Cargando…
Multi-Targeted Anticancer Activity of Imidazolate Phosphane Gold(I) Compounds by Inhibition of DHFR and TrxR in Breast Cancer Cells
A class of phosphane gold(I) compounds, made of azoles and phosphane ligands, was evaluated for a screening on the regards of Breast Cancer cell panels (BC). The compounds possess N-Au-P or Cl-Au-P bonds around the central metal, and they differ for the presence of aprotic or protic polar groups in...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821381/ https://www.ncbi.nlm.nih.gov/pubmed/33490036 http://dx.doi.org/10.3389/fchem.2020.602845 |
_version_ | 1783639412495613952 |
---|---|
author | Galassi, Rossana Luciani, Lorenzo Gambini, Valentina Vincenzetti, Silvia Lupidi, Giulio Amici, Augusto Marchini, Cristina Wang, Junbiao Pucciarelli, Stefania |
author_facet | Galassi, Rossana Luciani, Lorenzo Gambini, Valentina Vincenzetti, Silvia Lupidi, Giulio Amici, Augusto Marchini, Cristina Wang, Junbiao Pucciarelli, Stefania |
author_sort | Galassi, Rossana |
collection | PubMed |
description | A class of phosphane gold(I) compounds, made of azoles and phosphane ligands, was evaluated for a screening on the regards of Breast Cancer cell panels (BC). The compounds possess N-Au-P or Cl-Au-P bonds around the central metal, and they differ for the presence of aprotic or protic polar groups in the azoles and/or the phosphane moieties to tune their hydrophilicity. Among the six candidates, only the compounds having the P-Au-N environment and not displaying neither the hydroxyl nor carboxyl groups in the ligands were found active. The compounds were screened by MTT tests in SKBR3, A17, and MDA-MB231 cancer cells, and two compounds (namely the 4,5-dicyano-imidazolate-1yl-gold(I)-(triphenylphosphane, 5, and 4,5-dichloro-imidazolate-1yl-gold(I)-triphenylphosphane, 6) were found very cytotoxic, with the most active with an IC(50) value of 3.46 μM in MDA-MB231 cells. By performing enzymatic assays in the treated cells lysates, the residual enzymatic activity of dihydrofolate reductase (DHFR) has been measured after cell treatment for 4 or 12 h in comparison with control cells. Upon 12 h of treatment, the activity of DHFR was significantly reduced in both SKBR3 and A17 cells by compounds 5 and 6, but not in human MDA-MB231 cells; interestingly, it was found remarkably high after 4 h of treatment, revealing a time dependence for the DHFR enzymatic assays. The DHFR inhibition data have been compared to those for the thioredoxin reductase (TrxR), the most recognized molecular target for gold compounds. For this latter, similar residual activities (i.e., 37 and 49% for the match of SKBR3 cells and compound 5 or 6, respectively) were found. Binding studies on the regards of ct-DNA (calf-thymus-DNA) and of plasma transporters proteins, such as BSA (bovine serum albumin) and ATF (apo transferrin), were performed. As expected for gold compounds, the data support strong binding to proteins (K(sv) values range: 1.51 ÷ 2.46 × 10(4) M(−1)) and a weaker interaction with ct-DNA's minor groove (K(sv) values range: 1.55 ÷ 6.12 × 10(3) M(−1)). |
format | Online Article Text |
id | pubmed-7821381 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78213812021-01-23 Multi-Targeted Anticancer Activity of Imidazolate Phosphane Gold(I) Compounds by Inhibition of DHFR and TrxR in Breast Cancer Cells Galassi, Rossana Luciani, Lorenzo Gambini, Valentina Vincenzetti, Silvia Lupidi, Giulio Amici, Augusto Marchini, Cristina Wang, Junbiao Pucciarelli, Stefania Front Chem Chemistry A class of phosphane gold(I) compounds, made of azoles and phosphane ligands, was evaluated for a screening on the regards of Breast Cancer cell panels (BC). The compounds possess N-Au-P or Cl-Au-P bonds around the central metal, and they differ for the presence of aprotic or protic polar groups in the azoles and/or the phosphane moieties to tune their hydrophilicity. Among the six candidates, only the compounds having the P-Au-N environment and not displaying neither the hydroxyl nor carboxyl groups in the ligands were found active. The compounds were screened by MTT tests in SKBR3, A17, and MDA-MB231 cancer cells, and two compounds (namely the 4,5-dicyano-imidazolate-1yl-gold(I)-(triphenylphosphane, 5, and 4,5-dichloro-imidazolate-1yl-gold(I)-triphenylphosphane, 6) were found very cytotoxic, with the most active with an IC(50) value of 3.46 μM in MDA-MB231 cells. By performing enzymatic assays in the treated cells lysates, the residual enzymatic activity of dihydrofolate reductase (DHFR) has been measured after cell treatment for 4 or 12 h in comparison with control cells. Upon 12 h of treatment, the activity of DHFR was significantly reduced in both SKBR3 and A17 cells by compounds 5 and 6, but not in human MDA-MB231 cells; interestingly, it was found remarkably high after 4 h of treatment, revealing a time dependence for the DHFR enzymatic assays. The DHFR inhibition data have been compared to those for the thioredoxin reductase (TrxR), the most recognized molecular target for gold compounds. For this latter, similar residual activities (i.e., 37 and 49% for the match of SKBR3 cells and compound 5 or 6, respectively) were found. Binding studies on the regards of ct-DNA (calf-thymus-DNA) and of plasma transporters proteins, such as BSA (bovine serum albumin) and ATF (apo transferrin), were performed. As expected for gold compounds, the data support strong binding to proteins (K(sv) values range: 1.51 ÷ 2.46 × 10(4) M(−1)) and a weaker interaction with ct-DNA's minor groove (K(sv) values range: 1.55 ÷ 6.12 × 10(3) M(−1)). Frontiers Media S.A. 2021-01-11 /pmc/articles/PMC7821381/ /pubmed/33490036 http://dx.doi.org/10.3389/fchem.2020.602845 Text en Copyright © 2021 Galassi, Luciani, Gambini, Vincenzetti, Lupidi, Amici, Marchini, Wang and Pucciarelli. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Chemistry Galassi, Rossana Luciani, Lorenzo Gambini, Valentina Vincenzetti, Silvia Lupidi, Giulio Amici, Augusto Marchini, Cristina Wang, Junbiao Pucciarelli, Stefania Multi-Targeted Anticancer Activity of Imidazolate Phosphane Gold(I) Compounds by Inhibition of DHFR and TrxR in Breast Cancer Cells |
title | Multi-Targeted Anticancer Activity of Imidazolate Phosphane Gold(I) Compounds by Inhibition of DHFR and TrxR in Breast Cancer Cells |
title_full | Multi-Targeted Anticancer Activity of Imidazolate Phosphane Gold(I) Compounds by Inhibition of DHFR and TrxR in Breast Cancer Cells |
title_fullStr | Multi-Targeted Anticancer Activity of Imidazolate Phosphane Gold(I) Compounds by Inhibition of DHFR and TrxR in Breast Cancer Cells |
title_full_unstemmed | Multi-Targeted Anticancer Activity of Imidazolate Phosphane Gold(I) Compounds by Inhibition of DHFR and TrxR in Breast Cancer Cells |
title_short | Multi-Targeted Anticancer Activity of Imidazolate Phosphane Gold(I) Compounds by Inhibition of DHFR and TrxR in Breast Cancer Cells |
title_sort | multi-targeted anticancer activity of imidazolate phosphane gold(i) compounds by inhibition of dhfr and trxr in breast cancer cells |
topic | Chemistry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821381/ https://www.ncbi.nlm.nih.gov/pubmed/33490036 http://dx.doi.org/10.3389/fchem.2020.602845 |
work_keys_str_mv | AT galassirossana multitargetedanticanceractivityofimidazolatephosphanegoldicompoundsbyinhibitionofdhfrandtrxrinbreastcancercells AT lucianilorenzo multitargetedanticanceractivityofimidazolatephosphanegoldicompoundsbyinhibitionofdhfrandtrxrinbreastcancercells AT gambinivalentina multitargetedanticanceractivityofimidazolatephosphanegoldicompoundsbyinhibitionofdhfrandtrxrinbreastcancercells AT vincenzettisilvia multitargetedanticanceractivityofimidazolatephosphanegoldicompoundsbyinhibitionofdhfrandtrxrinbreastcancercells AT lupidigiulio multitargetedanticanceractivityofimidazolatephosphanegoldicompoundsbyinhibitionofdhfrandtrxrinbreastcancercells AT amiciaugusto multitargetedanticanceractivityofimidazolatephosphanegoldicompoundsbyinhibitionofdhfrandtrxrinbreastcancercells AT marchinicristina multitargetedanticanceractivityofimidazolatephosphanegoldicompoundsbyinhibitionofdhfrandtrxrinbreastcancercells AT wangjunbiao multitargetedanticanceractivityofimidazolatephosphanegoldicompoundsbyinhibitionofdhfrandtrxrinbreastcancercells AT pucciarellistefania multitargetedanticanceractivityofimidazolatephosphanegoldicompoundsbyinhibitionofdhfrandtrxrinbreastcancercells |